Targeting the cancer initiating cell: The ultimate target for cancer therapy

Current Pharmaceutical Design

Volumn 18, Issue 13, 2012, Pages 1784-1795

  McCubrey, James A ^a   Steelman, Linda S ^a   Abrams, Stephen L ^a   Misaghian, Negin ^a   Chappell, William H ^a   Bäsecke, Jörg ^b   Nicoletti, Ferdinando ^c   Libra, Massimo ^c   Ligresti, Giovanni ^c   Stivala, Franca ^c   Maksimovic Ivanic, Danijela ^d   Mijatovic, Sanja ^d   Montalto, Giuseppe ^e   Cervello, Melchiorre ^f   Laidler, Piotr ^g   Bonati, Antonio ^h   Evangelisti, Camilla ^f   Cocco, Lucio ⁱ   Martelli, Alberto M ^f,i  

^a EAST CAROLINA UNIVERSITY   (United States)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c UNIVERSITY OF CATANIA   (Italy)

^d UNIVERSITY OF BELGRADE   (Serbia)

^e UNIVERSITY OF PALERMO   (Italy)

^f CNR   (Italy)

^g JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^h UNIVERSITY HOSPITAL OF PARMA   (Italy)

ⁱ UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Akt; mTOR; PI3K; PTEN; Targeted therapy; Therapeutic sensitivity

Indexed keywords

4 AMINO 6 [2 [[4 (DIETHYLAMINO) 1 METHYLBUTYL]AMINO] 6 METHYL 4 PYRIMIDINYL] 2 METHYLQUINOLINE; ALDEHYDE DEHYDROGENASE; ARSENIC TRIOXIDE; BCR ABL PROTEIN; BETA CATENIN; BREAST CANCER RESISTANCE PROTEIN; DASATINIB; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MATRIX METALLOPROTEINASE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN KINASE B; RAPAMYCIN; STAT5 PROTEIN; TOZASERTIB; TRANSCRIPTION FACTOR FOXO; WNT PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STEM CELL; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; CELL RENEWAL; CHROMOSOMAL INSTABILITY; CHRONIC MYELOID LEUKEMIA; CLONAL EVOLUTION; COLON CARCINOMA; DRUG TARGETING; DRUG TRANSPORT; DRUG UPTAKE; GENE MUTATION; GLIOBLASTOMA; HEMATOPOIETIC STEM CELL; HUMAN; LEUKEMIA; LEUKEMOGENESIS; LIVER CELL CARCINOMA; LUNG CARCINOMA; MATHEMATICAL MODEL; MEDULLOBLASTOMA; MELANOMA; MICROENVIRONMENT; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROSTATE CARCINOMA; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; XENOTRANSPLANTATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AGENTS; HUMANS; MICE; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 84860146509     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799859701     Document Type: Review

References (144)

1. Campbell LL, Polyak K. Breast tumor heterogeneity: Cancer stem cells or clonal evolution? Cell Cycle 2007; 6: 2332-2338.
2. Dick JE. Stem cells: Self-renewal written in blood. Nature 2003; 423: 231-233.
3. Dick JE. Breast cancer stem cells revealed. Proc Natl Acad Sci USA 2003; 100: 3547-3549.
4. Till JE, McCulloch EA. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res 1961; 14: 213-222.
5. Rizo A, Vellenga E, de Haan G, Schuringa JJ. Signaling pathways in self-renewing hematopoietic and leukemic stem cells: Do all stem cells need a niche? Hum Mol Genet 2006; 15: R210-R219.
6. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645-648.
7. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-737.
8. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988.
9. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cells. Nature Reviews Cancer 2009; 9: 265-263.
10. Mailtand NJ, Collins AT. Prostate cancer stem cells: A new target of therapy. J Clin Oncol 2007; 26: 2862-2870.
11. Lawson DA, Witte ON. Stem cells in prostate cancer initiation and progression. J Clin Invest 2007; 117: 2044-2050.
12. Marian CO, Shay JW. Prostate tumor-initiating cells: A new target for telomerase inhibition therapy? Biochimica et Biophysica Acta 2009; 1792: 289-296.
13. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
14. Sullivan JP, Minna JD, Shay JW. Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy. Cancer Metastasis Rev 2010; 29: 61-72.
15. Chiu PP, Jiang H, Dick JE. Leukemia-initiating cells in human T lymphoblastic leukemia exhibit glucocorticoid resistance. Blood 2010; 116: 5268-5279.
16. Sehl ME, Sinsheimer JS, Zhou H, Lange KL. Differential destruction of stem cells: implications for targeted cancer stem cell therapy. Cancer Res 2009; 69: 9481-9489.
17. Dick JE. Stem cell concepts renew cancer research. Blood 2008; 112: 4793-4807.
18. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8: 755-768.
19. Rosen JM, Jordan CT. The increasing complexity of the cancer stem cell paradigm. Science 2009; 324: 1670-1673.
20. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002; 100: 1532-1542.
21. Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1: 313-323.
22. Barabe F, Kennedy, JA, Hope KJ, Dick J.E. Modeling the initiation and progression of human acute leukemia in mice. Science 2007; 316: 600-604.
23. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117-125.
24. Lemoli RM, Salvestrini V, Bianchi E, et al. Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. Blood 2009; 114: 5191-5200.
25. Odoux C, Fohrer H, Hoppo T, et al. A stochastic model for cancer stem cell origin in metastatic colon cancer. Cancer Res 2008; 68: 6932-6941.
26. Takebe N, Ivy SP. Controversies in cancer stem cells: Targeting embryonic signaling pathways. Clin Cancer Res 2010; 16: 3106-3112.
27. Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004; 351: 657-667.
28. Guibal FC, Alberich-Jorda M, Hirai H, et al. Identification of a myeloid committed progenitor as the cancer-initiating cell in acute promyelocytic leukemia. Blood, 2009, 114, 5415-5425.
29. Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB. Tumour-initiating cells: Challenges and opportunities for anticancer drug discovery. Nat Rev Cancer 2009; 8: 806-823.
30. Kelly PN, Dakic A, Adams JM, Nutt SL, Strasser A. Tumor growth need not be driven by rare cancer stem cells. Science 2007; 317: 337.
31. Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 2004; 5: 738-743.
32. Jin L, Lee EM, Ramshaw HS, et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 2009: 5: 31-42.
33. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature 2008; 456: 593-598.
34. Labarge MA. The difficulty of targeting cancer stem cell niches. Clin Cancer Res 2010; 16: 3121-3129.
35. Bonnet D, Bhatia M, Wang JC, Kapp U, Dick JE. Cytokine treatment or accessory cells are required to initiate engraftment of purified primitive human hematopoietic cells transplanted at limiting doses into NOD/SCID mice. Bone Marrow Transplant 1999; 23: 203-209.
36. Hill RP, Milas L. The proportion of stem cells in murine tumors. Int J Radiat Oncol Biol Phys 1989; 16: 513-518.
37. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-737.
38. Taussig DC, Miraki-Moud F, Anjos-Afonso F, et al. Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiatingcells. Blood 2008; 112: 568-575.
39. Abrahamsson AE, Geron I, Gotlib J, et al. Glycogen synthase kinase 3 beta missplicing contributes to leukemia stem cell generation. Proc Natl Acad Sci USA 2009; 106: 3925-3929.
40. Cox CV, Martin HM, Kearns PR, Virgo P, Evely RS, Blair A. Characterization of a progenitor cell population in childhood T-cell acute lymphoblastic leukemia. Blood 2007; 109: 674-682.
41. Park SY, Lee HE, Li H, Shipitsin M, Gelman R, Polyak K. Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res 2010; 16: 876-887.
42. Eaton CL, Colombel M, van der Pluijm G, et al. Evaluation of the frequency of putative prostate cancer stem cells in primary and metastatic prostate cancer. Prostate 2010; 70: 875-882.
43. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-1037.
44. Sikandar SS, Pate KT, Anderson S, et al. NOTCH signaling is required for formation and self-renewal of tumor-initiating cells and for repression of secretory cell differentiation in colon cancer. Cancer Res 2010; 70: 1469-1478.
45. Eramo A, Lotti F, Sette G, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008; 15: 504-514.
46. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
47. Yamashita T, Honda M, Nio K, et al. Oncostatin m renders epithelial cell adhesion molecule positive liver cancer stem cells sensitive to 5-Fluorouracil by inducing hepatocytic differentiation. Cancer Res 2010; 70: 4687-4697.
48. Goodell MA, Rosenzweig M, Kim H, et al. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med 1997; 3: 1337-1345.
49. Jakubikova J, Adamia S, Kost-Alimova M, et al. Lenalidomide targets clonogenic side population in multiple myeloma: Pathophysiologic and clinical implications. Blood 2011;117:4409-4419.
50. Yamazaki J, Mizukami T, Takizawa K, et al. Identification of cancer stem cells in a Taxtransgenic (Tax-Tg) mouse model of adult T-cell leukemia/lymphoma. Blood 2009; 114: 2709-2720.
51. Moshaver B, van Rhenen A, Kelder A, et al. Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia. Stem Cells 2008; 26: 3059-3067.
52. Salcido CD, Larochelle A, Taylor BJ, Dunbar CE, Varticovski L. Molecular characterisation of side population cells with cancer stem cell-like characteristics in small-cell lung cancer. Br J Cancer 2010; 102: 1636-1644.
53. Mimeault M, Johansson SL, Henichart JP, Depreux P, Batra SK. Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells. Mol Cancer Ther 2010; 9: 617-630.
54. Nakanishi T, Chumsri S, Khakpour N, et al. Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling. Br J Cancer 2010; 102: 815-826.
55. Harris MA, Yang H, Low BE, et al. Cancer stem cells are enriched in the sidepopulation cells in a mouse model of glioma. Cancer Res 2008; 68: 10051-10059.
56. Chiba T, Miyagi S, Saraya A, et al. The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma. Cancer Res 2008; 68: 7742-7749.
57. Chiba T, Kita K, Zheng YW, et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 2006; 44: 240-251.
58. Ravandi F, Estrov Z. Eradication of leukemia stem cells as a new goal of therapy in leukemia. Clin Cancer Res 2006; 12: 340-344.
59. Gal H, Amariglio N, Trakhtenbrot L, et al. Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells. Leukemia 2006; 20: 2147-2154.
60. de Jonge-Peeters SD, Kuipers F, de Vries EG, Vellenga E. ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance. Crit Rev Oncol Hematol 2007; 62: 214-226.
61. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nature Reviews Cancer 2002; 2: 48-58.
62. de Grouw EP, Raaijmakers MH, Boezeman JB, et al. Preferential expression of a high number of ATP binding cassette transporters in both normal and leukemic CD34+CD38- cells. Leukemia 2006; 20: 750-754.
63. Krause DS, van Etten RA. Right on target: Eradicating leukemic stem cells. Trends Mol Med 2007; 13: 470-481.
64. Ross DD. Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome. Best Pract Res Clin Haema-tol 2004; 17: 641-651.
65. Ross DD. Novel mechanisms of drug resistance in leukemia. Leukemia 2000; 14: 467-473.
66. Fisher GA, Sikic BI. Clinical studies with modulators of multidrug resistance. Hematol Oncol Clin North Am 1995; 9: 363-382.
67. Greenberg PL, Lee SJ, Advani R, et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995). J Clin Oncol 2004; 22: 1078-1086.
68. Cheung AM, Wan TS, Leung JC, et al. Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential. Leukemia 2007; 21: 1423-1430.
69. Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004; 18: 189-218.
70. Jaiswal S, Traver D, Miyamoto T, Akashi K, Lagasse E, Weissman IL. Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias. Proc Natl Acad Sci USA 2003; 100: 10002-10007.
71. Jiang X, Zhao Y, Smith C, et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 2007; 21: 926-935.
72. Jiang X, Saw KM, Eaves A, Eaves C. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. J Natl Cancer Inst 2007; 99: 680-693.
73. Roeder I, Horn M, Glauche I, Hochhaus A, Mueller MC, Loeffler M. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med 2006; 12: 1181-1184.
74. Cobaleda C, Gutierrez-Cianca N, Perez-Losada J, et al. A primitive hematopoietic cell is the target for the leukemic transformation in human Philadelphia-positive acute lymphoblastic leukemia. Blood 2000; 95: 1007-1013.
75. Michor F, Hughes TP, Iwasa Y, et al. Dynamics of chronic myeloid leukemia. Nature 2005; 435: 1267-1270.
76. Michor F. Mathematical models of cancer stem cells. J Clin Oncol 2008; 26: 2854-2861.
77. Michor F. Quantitative approaches to analyzing Imatinib-treated chronic myeloid leukemia. Trends in Pharmacological Sciences 2007; 28: 197-199.
78. Dingli D, Traulsen A, Michor F. (A)symmetric stem cell replication and cancer. PLOS computational biology 2007; 3: 482-487.
79. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-880.
80. Thomas EK, Cancelas JA, Zheng Y, Williams DA. Rac GTPases as key regulators of p210-BCR-ABL-dependent leukemogenesis. Leukemia 2008; 22: 898-904.
81. Cancelas JA, Lee AW, Prabhakar R, Stringer KF, Zheng Y, Williams DA. Rac GTPases differentially integrate signals regulating hematopoietic stem cell localization. Nat Med 2005; 11: 886-891.
82. Gu Y, Filippi MD, Cancelas JA, et al. Hematopoietic cell regulation by Rac1 and Rac2 guanosine triphosphatases. Science 2003; 302: 445-449.
83. Wang Y, Cai D, Brendel C, et al. Adaptive secretion of granulo-cyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR-ABL + progenitors via JAK-2/STAT-5 pathway activation. Blood 2007; 109: 2147-2155.
84. Yang FC, Atkinson SJ, Gu Y, et al. Rac and Cdc 42 GTPases control hematopoietic stem cell shape, adhesion, migration, and mobilization. Proc Natl Acad Sci USA 2001; 98: 5614-8.
85. Thomas EK, Cancelas JA, Chae HD, et al. Rac guanosine triphosphates represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease Cancer Cell 2007; 12: 467-78.
86. Hu Y, Swerdlow S, Duffy TM, Weinmann R, Lee FY, Li S. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad USA 2006; 103: 16870-16875.
87. Li S, Li D. Stem cell and kinase activity-independent pathway in resistance of leukaemia to BCR-ABL inhibitors. J Cell Mol Med 2007; 11: 1251-62.
88. Hu Y, Liu Y, Pelletier S, et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 2004; 36: 453-61.
89. Danhauser-Riedl S, Warmuth M, Druker BJ, Emmerich B, Hellek M. Activation of Src kinases p53/p56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Res 1996; 56: 3589-3596.
90. Warmuth M, Bergmann M, Priess A, Hauslmann K, Emmerich B, Hallek M. The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb-2-binding site of Bcr. J Biol Chem 1997; 272: 33260-33270.
91. Feinstein E, Cimino G, Gale RP, et al. P53 in chronic myelogenous leukemia in acute phase. Proc Natl Acad USA 1991; 88: 6293-6297.
92. Sill H, Goldman JM, Cross NC. Homozygous deletions of the p16 tumor-suppressor genes are associated with lymphoid transformation of chronic myeloid leukemia. Blood 1995; 85: 2013-2016.
93. Towatari M, Adachi K, Kato H, Sato H. Absence of the human retinoblastoma gene product in the megakaryoblastic crisis of chronic myelogenous leukemia. Blood 1991; 78: 2178-2181.
94. Williams RT, Roussel MF, Sherr CJ. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Ablinduced acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2006; 103: 6688-6693.
95. Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman SJ. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007; 109: 500-502.
96. Cheetham GM, Charlton PA, Golec JM, Pollard JR. Structural basis for potential inhibition of the Aurora kinases and a T315I multidrug resistant mutant form of Abl by VX-680. Cancer Lett 2007; 251: 323-329.
97. Schroeder JA, Adriance MC, Thompson MC, Camenisch TD, Gendler SJ. MUC1 alters beta-catenin-dependent tumor formation and promotes cellular invasion. Oncogene 2003; 22: 1324-1332.
98. Haraguchi K, Nishida A, Ishidate T, Akiyama T. Activation of P-catenin-TCF-mediated transcription by non-receptor tyrosine kinase v-Src. Biochem Biophys Res Commun 2004; 313: 841-844.
99. Mikesch JH, Steffen B, Berdel, Serve H, Muller-Tidow C. The emerging role of Wnt Signaling in the pathogenesis of acute myeloid leukemia. Leukemia 2007; 21: 1638-1647.
100. Kawano Y, Kypta R. Secreted antagonists of the Wnt signaling pathway. J Cell Sci 2003; 116: 2627-2634.
101. Chim CS, Chan WWL, Pang A, Kwong YL. Preferential methylation of Wnt inhibitor factor-1 in acute promyelocytic leukemia: An independent poor prognostic factor. Leukemia 2006; 20: 907-909.
102. Reya T, Duncan AW, Ailles L, et al. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 2003; 423: 409-414.
103. Zhao C, Blum J, Chen A, et al. Loss of P-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 2007; 12: 528-541.
104. Austin TW, Solar GP, Ziegler FC, Liem L, Matthews WA. A role for the Wnt gene family in hematopoiesis: Expansion of multilineage progenitor cells. Blood 1997; 89: 3624-3635.
105. van den Berg DJ, Sharma AK, Bruno E, Hoffman R. Role of members of the Wnt gene family in human haematopoiesis. Blood 1998; 89: 3189-3202.
106. Bhardwaj G, Murdoch B, Wu D, et al. Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation. Nat Immunol 2001; 2: 172-180.
107. Varnum-Finney B, Xu L, Brashem-Stein C, et al. Pluripotent, cytokine-dependent, hematopoietic stem cells are immortalized by constitutive Notch1 signaling. Nat Med 2000; 6: 1278-1281.
108. Hing HK, Sun X, Artavanis-Tsakonas S. Modulation of wingless signaling by Notch in Drosophilia. Mech Dev 1994; 47: 261-268.
109. Brandts CH, Sargin B, Rode M, et al. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. Cancer Res 2005; 65: 9643-9650.
110. Mizuki M, Schwable J, Steur C, et al. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific mutations. Blood 2003; 101: 3164-3173.
111. Tickenbrock L, Schwable J, Wiedehage M, et al. Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction. Blood 2005; 105: 3699-3706.
112. Lapidot T, Kollet O. The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopula-tion of transplanted immune-deficient NOD/SCID and NOD/SCID/B2 m(null) mice. Leukemia 2002; 16: 1992-2003.
113. Willert K, Brown JD, Danenberg E, et al. Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature 2003; 423: 448-452.
114. Teixido J, Hemler ME, Greenberger JS, Anklesaria P. Role of beta 1 and beta 2 integrins in the adhesion of human CD34hi stem cells to bone marrow stroma. J Clin Invest 1992; 90: 358-367.
115. Hirsch E, Iglesias A, Potocnik AJ, Hartmann U, Fassler R. Impaired migration but not differentiation of haematopoietic stem cells in the absence of beta1 integrins. Nature 1996; 380: 171-175.
116. Lin LI, Lin DT, Chang CJ, Lee CY, Tang JL, Tien HF. Marrow matrix metalloproteinases (MMPs) and tissue inhibitors of MMP in acute leukaemia: potential role of MMP-9 as a surrogate marker to monitor leukaemic status in patients with acute myelogenous leukaemia. Br. J. Haematol 2002; 117: 835-841.
117. Williams DA, Cancelas JA. Leukaemia: Niche retreats for stem cells. Nature 2006; 444: 827-828.
118. Krause DS Lazarides K, von Adrian UH, Van Etten RA. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med 2006; 12: 1175-1180.
119. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F. Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cell. Nat Med 2006; 12: 1167-1174.
120. Yilmaz NH, Valdez R, Theisen BK, et al. PTEN-dependence distinguishes haematopoietic stem cells from leukemia-initating cells. Nature 2006; 441: 475-478.
121. Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY. CD133+ cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008; 27: 1749-1758.
122. Zhou J, Wulkuhle H, Zhang H, et al. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci USA 2007; 104: 16158-16163.
123. Hambardzumyan D, Becher OJ, Rosenblum MK, Pandolfi PP, Manova-Todorova K, Holland EC. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev 2008; 22: 436-448.
124. Li X, Lewis MT, Huang J, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008; 100: 672-679.
125. Shafee N, Smith CR, Wei S, et al. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res 2008; 68: 3243-3250.
126. Misaghian N, Ligresti G, Steelman LS, et al. Targeting the leukemic stem cell - the holy grail of leukemia therapy. Leukemia 2009; 23: 25-42.
127. Korkaya H, Paulson A, Charafe-Jauffret E, et al. Regulation of mammary stem/progenitor cells by PTEN/Akt/p-catenin signaling. PLOS Biology 2009; 7: 1-14.
128. Ito K, Bernardi R, Pandolfi PP. A novel signaling network as a critical rheostat for the biology and maintenance of the normal stem cell and the cancer-initiating cell. Curr Opin Genet Dev 2009; 19: 51-59.
129. McCubrey JA, Abrams SL, Stadelman K, et al. Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells. Adv Enzyme Regul 2010; 50: 285-307.
130. Lee JY, Nakada D, Yilmaz OH, et al. mTOR Activation induces tumor suppressors that inhibit leukemogenesis and deplete hematopoietic stem cells after Pten deletion. Cell Stem Cell 2010; 7: 593-605.
131. Chen C, Liu Y, Liu R, et al. TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species. J Exp Med 2008; 205: 2397-2408.
132. Gan B, Sahin E, Jiang S, et al. mTORC1-dependent and -independent regulation of stem cell renewal, differentiation, and mobilization. Proc Natl Acad Sci USA 2008; 105: 19384-19389.
133. Hashimoto Y, Skacel M, Adams JC. Roles of facin in human carcinoma motility and signaling: Prospects for a novel biomarker? Int J Biochem Cell Biol 2005; 37: 1787-1804.
134. Tothova Z, Kollipara R, Huntly BJ, et al. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell 2007; 128: 325-339.
135. Miyamoto K, Araki KY, Naka K, et al. Foxo3a is essential for maintenance of the hematopoietic stem cell pool. Cell Stem Cell 2007; 1: 101-112.
136. Ito K, Bernardi R, Morotti A, et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature 2008; 453: 1072-1079.
137. Bernardi R, Guernah I, Jin D, et al. PML inhibits HIF-1a translation and neoangiogeneis through repression of mTOR. Nature 2006; 442: 779-785.
138. Vicente-Dueñas C, Abollo-Jiménez F, Ruiz-Roca L, et al. The age of the target cell affects B-cell leukaemia malignancy. Aging 2010; 2:908-913.
139. Kemper K, Grandela C, Medema JP. Molecular identification and targeting of colorectal cancer stem cells. Oncotarget 2010; 1:387-395
140. Pajic M, Kersbergen A, van Diepen F, et al. Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1; p53-deficient mammary tumor cells in vivo. Cell Cycle 2010; 9: 3780-3791.
141. Peng C, Chen Y, Li D, Li S. Role of Pten in leukemia stem cells. Oncotarget 2010;1:156-160.
142. Bortolomai I, Canevari S, Facetti I, et al. Tumor initiating cells: Development and critical characterization of a model derived from the A431 carcinoma cell line forming spheres in suspension. Cell Cycle 2010; 9:1194-1206.
143. Martelli AM, Evangelisti C, Chiarini F, McCubrey JA. The phos-phatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget 2010; 1:89-103.
144. [Adams JR, Schachter NF, Liu JC, Zacksenhaus E, Egan SE. Elevated PI3K signaling drives multiple breast cancer subtypes. Onco-target 2011 In press.